Hepatitis B virus infection in Iran; Changing the epidemiology

Iranian Journal of Clinical Infectious Diseases

Volumn 5, Issue 1, 2010, Pages 51-61

  Alavian, Seyed Moayed ^a  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN;

ARTICLE; BLOOD DONOR; HEMODIALYSIS PATIENT; HEMOPHILIA; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION RISK; IRAN; MASS IMMUNIZATION; RISK ASSESSMENT; RISK FACTOR; SEROEPIDEMIOLOGY; SEROPREVALENCE; THALASSEMIA; VIRUS ENTRY; VIRUS TRANSMISSION;

EID: 80053418042     PISSN: 17355109     EISSN: 20081081     Source Type: Journal    
DOI: None     Document Type: Article

References (104)

1. Alavian SM, Fallahian F, Bagheri-Lankarani K. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis. 2007;16(4):403-6.
2. Merat SH, Malekzadeh R, Rezvan H, Khatibian M. Hepatitis B in Iran. Arch Iran Med. 2000;3:192-201.
3. Adibi P, Ghassemian R, Alavian SM, Ranjbar M, Mohammadalizadeh AH, Nematizadeh F, et al. Effectiveness of hepatitis B vaccination in children of chronic hepatitis B mothers. Saudi Med J. 2004;25:1414-18.
4. Kabir A, Alavian SM, Ahanchi N, Malekzadeh R. Combined passive and active immunoprophylaxis for preventing perinatal transmission of the hepatitis B virus in infants born to HBsAg positive mothers in comparison with vaccine alone. Hepatol Res. 2006;36(4):265-71.
5. Farzadegan H, Shamszad M, Noori-Arya K. Epidemiology of viral hepatitis among Iranian population; a viral marker study. Ann Acad Med Singapore.1980;9(2):144-8.
6. Malekzadeh R, Khatibian M, Rezvan H. Viral hepatitis in the world and Iran. Journal of Iranian Medical Council. 1997;15:183-200.
7. st edition. Turin: Minerva Media. 1997;p:678-80.
8. Amini S, Mahmoodi MF, Andalibi S, Solati AA. Seroepidemiology of hepatitis B, delta and human immunodeficiency virus infections in Hamadan province, Iran: a population based study. J Trop Med Hyg. 1993;96:277-87.
9. Ghavanini AA, Sabri MR. Hepatitis B surface antigen and anti-hepatitis C antibodies among blood donors in the Islamic Republic of Iran. East Mediterr Health J. 2000;6:1114-6.
10. Merat S, Malekzadeh R, Rezvan H, Khatibian M. Hepatitis B in Iran. Arch Iran Med. 2000;3:192-201.
11. Bagheri Lankarani K, Saberi Froozi M, Nabipoor I, Fattahi F, Sarafrazyazdi M, Malekzadeh R, et al. Reassesment of the role of hepatitis B and C viruses in southern Iran. Iranian Journal of Medical Sciences 1999;24:117-21.
12. Shamszad M, Farzadegan H. Hepatitis B related cirrhosis and hepatocellular carcinoma in Iran. Journal of Iranian Medical Council. 1982;8:228.
13. Zali MR, Mohammad K, Noorbala AA, Noorinayer B, Shahraz S. Rate of hepatitis B seropositivity following mass vaccination in the Islamic Republic of Iran. East Mediterr Health J. 2005;11:62-7.
14. Alavian SM. Ministry of Health in Iran is serious about controlling hepatitis B. Hepatitis Monthly 2007;7:3-5.
15. Alavian SM, Hajariazdeh B, Ahmadzad Asl M, Kabir A, Bagheri Lankarani K. Hepatitis B virus infection in Iran: a systematic review. Hepatitis Monthly 2008;8(4):281-94.
16. Alavian SM, Gooya MM, Hajarizadeh B, Esteghamati AR, Moeinzadeh AM, Haghazali M, et al. Mass vaccination campaign against hepatitis B in adolescents in Iran: estimating coverage using administrative data. Hepatitis Monthly 2009;9(3):189-195.
17. Hasanpour SE, Arasteh E, Ghorbani S, Mahdavi S. Prevalence of hepatitis B, hepatitis C and HIV infection in 15 year and older patients admitted in hand surgery emergency. Scientific Journal of Kourdestan University of Medical Sciences. 2003;8(1):25-33. (In Persian)
18. Parsania M, Poopak B, Khavari Z, Radpoor M. Specify the hepatitis B carriers among 1595 patientseligible for surgery referring to Amiralmomenin hospital assigned to Islamic Azad University. The 3th Iranian Congress of Virology. 21-23 January 2006, Tehran, Iran.
19. Merat S, Rezvan H, Nouraie M, Jamali A, Assari S, Abolghasemi H, et al. The prevalence of hepatitis B surface antigen and anti-hepatitis B core antibody in Iran: a population-based study. Arch Iran Med. 2009;12(3):225-31.
20. Abdolahi N, Keshtkar AA, Semnani S, Roshandel GR, Beshrat S, Joshaghani HR, et al. HBV Seroprevalence among Golestan adults. Iranian Journal of Epidemiology 2006;4(1):35-40. (In Persian)
21. Bayat-Makou J, Shahnazi A, Koushavar H. Prevalent infections in north-west region of Tabriz. Medical Journal of Tabriz University of Medical Sciences 2003;59:30-34. (In Persian)
22. Montazam SH, Tanomand A, Khaky AA, Sany AA, Nabi MN. Seroprevalence of HBV in children and adults for estimating of national vaccine program, Malekan city, Iran 2004. J Gastroenterol Hepatol 2006;21:A111.
23. Montazam SH, Kafshnoochi M, Tanoomand A. Seroprevalence of HIV, hepatitis B and hepatitis C among married people in Malekan district, a retrospective study from September 2004 to September 2005. The 3rd National Epidemiology Congress of Iran. 10-12 May, 2006, Kerman, Iran.
24. Alizadeh AHM, Ranjbar M, Ansari S, MirArab A, Alavian SM, Mohammad K, et al. Seroprevalence of hepatitis B in Nahavand, Islamic Republic of Iran. East Mediterr Health J. 2006;12(5):528-37.
25. Ataie B, Javadi A, Adibi P, Shoaie P. HBV markers in Esfahan province 1384. The 15th Iranian Congress on Infectious Diseases and Tropical Medicine. 16-20 December, 2006, Tehran, Iran.
26. Kazerani H. Epidemiologic evaluation of positive cases for HCV, HBV and HIV in the patients on surgery and aggressive cardiac interventions in Emam Ali hospital in Kermanshah. Scientific Journal of Kourdestan University of Medical Sciences. 2006; 11:42-7. (In Persian)
27. Khedmat H, Alavian SM, Miri SM, Amini M, Abolghasemi H, Hajibeigi B, et al. Trends in seroprevalence of hepatitis B, hepatitis C, HIV, and syphilis infections in Iranian blood donors from 2003 to 2005. Hepatitis Monthly 2009;9(1):24-8.
28. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl JMed. 1999;341:556-62.
29. Kafi-abad SA, Rezvan H, Abolghasemi H. Trends in prevalence of hepatitis B virus infection among Iranian blood donors, 1998-2007. Transfus Med. 2009;19(4):189-94.
30. Rosini N, Mousse D, Spada C, Treitinger A. Seroprevalence of HbsAg, anti-HBc and anti-HCV in Southern Brazil, 1999-2001. Braz J Infect Dis. 2003;7(4):262-7.
31. Soldan K, Barbara JA, Ramsay ME, Hall AJ. Estimation of the risk of hepatitis B virus, hepatitis C virus and human immunodeficiency virus infectious donations entering the blood supply in England, 1993- 2001. Vox Sang. 2003;84(4):274-86.
32. Soldan K, Barbara JA, Dow BC. Transfusiontransmitted hepatitis B virus infection in the UK: a small and moving target. Vox Sang. 2002;83(4):305-8.
33. Vahid T, Alavian SM, Kabir A, Kafaee J, Yektaparast B. Hepatitis B prevalence and risk factors in blood donors in Ghazvin, I.R. Iran. Hepatitis Monthly 2005;5:117-22.
34. Attarchi Z, Ghafouri M, Hajibeigi B, Assari SH, Alavian SM. Donor deferral and blood-borne infections in blood donors of Tehran. Scientific Journal of Iranian Blood Transfusion Organization Research Center 2005;7(2):353-64.
35. Sali S. HBV vaccination in chronic renal failure patients. Hepatitis Monthly 2006;6(1):25-9.
36. Ambuhl PM, Binswanger U, Renner EL. Epidemiology of chronic hepatitis B and C among dialysis patients in Switzerland. Schweiz Med Wochenschr. 2000;130(10):341-8.
37. Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial. 2005;18(1):52-61.
38. Alavian SM. Hepatitis C, chronic renal failure, control is possible! Hepatitis Monthly 2006;6(2):551-52.
39. Alavian SM, Bagheri-Lankarani K, Mahdavi- Mazdeh M, Nourozi S. Hepatitis B and C in dialysis units in Iran: Changing the epidemiology. Hemodial Int. 2008;12(3):378-82.
40. Kumar D, Arora A, Singh NP, Kohli R, Kar P, Das BC. Hepatitis G virus infection in hemodialysis patients from urban Delhi. Ren Fail. 2005;27(1):87-93.
41. Vladutiu DS, Cosa A, Neamtu A, State D, Braila M, Gherman M, et al. Infections with hepatitis B and C viruses in patients on maintenance dialysis in Romania and in former communist countries: yellow spots on a blank map? J Viral Hepat. 2000;7(4):313-9.
42. De Castro L, Araujo NM, Sabino RR, Alvarenga F, Yoshida CF, Gomes SA. Nosocomial spread of hepatitis B virus in two hemodialysis units, investigated by restriction fragment length polymorphism analysis. Eur J Clin Microbiol Infect Dis. 2000;19(7):531-7.
43. Lewis-Ximenez LL, Oliveira JM, Mercadante LA, De Castro L, Santa Catharina W, Stuver S, et al. Serological and vaccination profile of hemodialysis patients during an outbreak of hepatitis B virus infection. Nephron. 2001;87(1):19-26.
44. Kheradpezhouh M, Taremi M, Gachkar L, Aghabozorgi S, Khoshbaten M. Presence and significance of transfusion-transmitted virus infection in Iranian patients on maintenance hemodialysis. J Microbiol Immunol Infect. 2007;40(2):106-11.
45. Busek SU, Baba EH, Tavares Filho HA, Pimenta L, Salomao A, Correa-Oliveira R, et al. Hepatitis C and hepatitis B virus infection in different hemodialysis units in Belo Horizonte, Minas Gerais, Brazil. Mem Inst Oswaldo Cruz. 2002;97(6):775-8.
46. Carrilho FJ, Moraes CR, Pinho JR, Mello IM, Bertolini DA, Lemos MF, et al. Hepatitis B virus infection in Hemodialysis Centers from Santa Catarina State, Southern Brazil. Predictive risk factors for infection and molecular epidemiology. BMC Public Health. 2004;4:13-16.
47. Otedo AE, Mc'Ligeyo SO, Okoth FA, Kayima JK. Seroprevalence of hepatitis B and C in maintenance dialysis in a public hospital in a developing country. S Afr Med J. 2003;93(5):380-4.
48. Ferreira RC, Teles SA, Dias MA, Tavares VR, Silva SA, Gomes SA, et al. Hepatitis B virus infection profile in hemodialysis patients in Central Brazil: prevalence, risk factors, and genotypes. Mem Inst Oswaldo Cruz. 2006;101(6):689-92.
49. Hosseini-Moghaddam SM, Keyvani H, Kasiri H, Kazemeyni SM, Basiri A, Aghel N, et al. Distribution of hepatitis C virus genotypes among hemodialysis patients in Tehran; a multicenter study. J Med Virol. 2006;78(5):569-73.
50. Abolghasemi H, Maghsudlu M, Amini Kafi-Abad S, Cheraghali A. Introduction to Iranian Blood Transfusion Organization blood safety in Iran. Iran J Public Health. 2009;38(1):82-7.
51. Sharifi V, Yousefi-Nooraie R, Rahimi-Movaqar A, Mesgarpour B, Basirnia A. Development of a quality assessment tool for prevalence studies in mental health. (In Press)
52. Mahdavimazdeh M, Hosseini-Moghaddam SM, Alavian SM, Yahyazadeh H. Hepatitis B Infection in hemodialysis patients in Tehran province, Iran. Hepatitis Monthly 2009;9(3):206-10.
53. Hung KY, Shyu RS, Huang CH, Tsai TJ, Chen WY. Viral hepatitis in continuous ambulatory peritoneal dialysis patients in an endemic area for hepatitis B and C infection: the Taiwan experience. Blood Purif. 1997;15(3):195-9.
54. Alavian SM, Hajarizadeh B. Remarkable difference in the mode of HCV transmission among hemodialysis patients and IVDAs. Gut. 2004;53(7):1057.
55. Alavian SM., Ardeshiri A, Hajarizadeh B. Prevalence of HCV, HBV and HIV infections among hemophiliacs. Hakim Research Journal 2003;2(6):45-51. (In Persian)
56. Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: Epidemiology of an emerging infection. Arch Iran Med. 2005;8:84-90.
57. Alavian SM. Hepatitis C virus infection: Epidemiology, risk factors and prevention strategies in public health in I.R. IRAN. Gastroenterology and Hepatology From Bed to Bench 2010;3(1):5-14.
58. Alavian SM. Hepatitis C infection in Iran; A review article. Iranian Journal of Clinical Infectious Disease 2009;4(1):47-59.
59. Javadzadeh-Shahshahani H, Attar M, Yavari MT, Savabieh SH. Study of the prevalence of hepatitis B, C and HIV infection in hemophilia and thalassemia population of Yazd in 2003. Scientific Journal of Iranian Blood Transfusion Organization Research Center 2006;2(7):315-22. (In Persian)
60. Torabi SE, Abed-Ashtiani K, Dehkhoda R, Moghaddam A, Bahram MK, Dolatkhah R, et al. Prevalence of hepatitis B, C and HIV in hemophiliac patients of East Azarbaijan in 2004. Scientific Journal of Iranian Blood Transfusion Organization Research Center 2006;2(Sup 7):291-9. (In Persian)
61. Sharifi-Mood B, Eshghi P, Sanei-Moghaddam E, Hashemi M. Hepatitis B and C virus infections in patients with hemophilia in Zahedan, southeast Iran. Saudi Med J. 2007;28(10):1516-9.
62. Mohammad-Alizadeh AH, Rezazadeh M, Ranjbar M, Hajilooyi M, Fallahian F, Moosavi SM, et al. Frequency of hepatitis B and C and their relation with factor VIII inhibitor in hemophiliac patients of Hamedan province, 2004. Pejouhesh, Journal of the Faculty of Medicine, Shahid Beheshti University of Medical Sciences 2006;30(2):119-23. (In Persian)
63. Mansour-Ghanaei F, Fallah MS, Shafaghi A, Yousefi-Mashhoor M, Ramezani N, Farzaneh F, et al. Prevalence of hepatitis B and C seromarkers andabnormal liver function tests among hemophiliacs in Guilan (northern province of Iran). Med Sci Monit. 2002;8(12):CR 797-800.
64. Abolghasemi H, Amid A, Zeinali S, Radfar MH, Eshghi P, Rahiminejad MS, et al. Thalassemia in Iran: epidemiology, prevention, and management. J Pediatr Hematol Oncol. 2007;29(4):233-8.
65. Alavian SM, Tabatabaei SV. Treatment outcome of chronic hepatitis C in sickle cell disease and thalassemic patients with interferon and ribavirin. Eur J Gastroenterol Hepatol. 2010;22(1):123-4.
66. Alavian SM, Tabatabaei SV. Therapy of hepatitis C in thalassemia: the influence of iron on achieving sustained viral response. Ann Hematol. 2010;89(2):215-216.
67. Mirmomen S, Alavian SM. Treatment of HCV Infection in multitransfused thalassemic patients: does liver iron status affect the outcome of response? Hepatitis Monthly 2005;5(1):111-13.
68. Mirmomen S, Alavian SM, Hajarizadeh B, Kafaee J, Yektaparast B, Zahedi MJ, et al. Epidemiology of hepatitis B, hepatitis C, and human immunodeficiency virus infections in patients with beta-thalassemia in Iran: a multicenter study. Arch Iran Med. 2006;9:319-23.
69. Zahedi MJ, Zand V, Tavakoli M, Hajariazdeh B, Alavian SM. The prevalence of hepatitis B and C among thalassemia major patients in Kerman, Iran, and the role of transfusion in infection acquisition. Govaresh. 2003;8(44):72-8. (In Persian)
70. Pedram M. Frequency of hepatitis B in the children with thalassemia major referring to thalassemia clinics of Ahwaz during one year. Scientific Medical Journal 2006;5(4):740-8. (In Persian)
71. Sali SH, Bashtar R, Alavian SM. Risk Factors in chronic hepatitis B infection: a case-control study. Hepatitis Monthly. 2005;5(4):109-15.
72. Alavian SM, Mostajabi P, Malekzadeh R, Azimi K, Vosoogh H, Sarrafi M, et al. Evaluation of hepatitis B transmission risk factors in Tehran blood donors. Govaresh. 2004;9:169-75. (In Persian)
73. Jahani MR, Alavian SM, Shirzad H, Kabir A, Hajarizadeh B. Distribution and risk factors of hepatitis B, hepatitis C, and HIV infection in a female population with illegal social behaviour. Sex Transm Infect. 2005;81(2):185.
74. Ali F, Aziz AA, Helmy MF, Mobdy AA, Darwish M. Prevalence of certain sexually transmitted diseases in Egypt. J Egypt Public Health Assoc. 1996;71(5-6):553-75.
75. Mujeeb SA, Khatri Y, Khanani R. Frequency of parenteral exposure and seroprevalence of HBV, HCV, and HIV among operation room personnel. J Hosp Infect. 1998;38(2):133-7.
76. Khan AJ. Unsafe injections and the transmission of hepatitis B and C in a Periurban community in Pakistan. Bull World Health Organ. 2000;78:956-63.
77. Alavian SM, Fallahian F, Lankarani KB. Comparison of seroepidemiology and transmission modes of viral hepatitis B in Iran and Pakistan. Hepatitis Monthly 2007;7(4):2233-38.
78. Alavian SM, Fallahian F, Bagheri-Lankarani K. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis. 2007;16(4):403-6.
79. Amini S, Mahmoodi MF, Andalibi S, Solati A. Seroepidemiology of hepatitis B, delta and human immunodeficiency virus infections in Hamadan province, Iran: A population based study. Journal of Tropical Medicine and Hygiene. 1993;96(5):277-87.
80. Farzadegan H, Shamszad M, Noori-Arya K. Epidemiology of viral hepatitis among Iranian population; A viral marker study. Ann Acad Med Singapore1980;9(2):144-148.
81. McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis. 2005;25(suppl 1):1-3.
82. McMahon BJ. Natural history of chronic hepatitis B; clinical implications. Medscape Journal of Medicine. 2008;10(4):91.
83. Alavi-Moghaddam M, Alavian SM, Hajibeigi B. Preliminary report on safety and response rate of pegylated interferon-alpha 2 a (pegasys) in genotype D chronic hepatitis B patients in Iran. Gastroenterology and Hepatology From Bed to Bench 2010;3(2):98-104.
84. Alavian SM. Chronic hepatitis B, diagnosis, therapy and prevention. Journal of Medical Faculty of Baqiyatallah University of Medical Sciences 2001;7(57):57-75. (In Persian)
85. Yosefirad M, Malekzadeh R, Khatibian M, Alavian SM, Rezvan H, Kamalian N, et al. Prospective controlled trial of interferon alpha-2b (INF) in Iranian patients with chronic hepatitis B (CHB). Gastroenterology. 1997;112:A1420.
86. Alavian SM. The efficacy of lamivudine in patients with chronic hepatitis B after one year. Govaresh. 2002;7(37-38):33-7. (In Persian)
87. Alavian SM. Therapeutic guideline for chronic hepatitis B. Journal of Medical Faculty of Baqiyatallah University of Medical Sciences. 2003;8(61):48-72. (In Persian)
88. Aghazadeh R, Alavian SM, Adibi P, Minakari M. Lamivudine or interferon alpha? this is the problem. Hepatitis Monthly. 2004;4(6):151-3.
89. Alavian S. What to treat with interferon? Hepatitis Monthly. 2004;4(6):23-9.
90. Alavian SM, Kabir A, Torabi HR. The efficacy of lamivudine in hepatitis B-related cirrhosis. Hepatitis Monthly. 2004;4(8):165-9.
91. Alavi-Moghaddam M, Alavian SM, Yadegarynia D. Comparing the efficacy of alpha-interferon and lamivudine in patients with chronic hepatitis B. Iranian Journal of Clinical Infectious Diseases. 2006;1(2):5-10.
92. Jahani MR, Alavian SM, Shirzad H, Kabir A, Hajarizadeh B. Distribution and risk factors of hepatitis B, hepatitis C, and HIV infection in a female population with illegal social behavior. Sexually Transmitted Infections. 2005;81(2):185.
93. Jahani MR, Motevalian SA, Mahmoodi M. Hepatitis B carriers in large vehicle drivers of Iran. Vaccine. 2003;21(17-18):1948-51.
94. Javadi AA, Avijgan M, Hafizi M. Prevalence of HBV and HCV infections and associated risk factors in addict prisoners. Iran J Public Health 2006;35(4):33-6.
95. Alavian SM. Hepatitis C in hemodialysis patients needs more attention for control and review the risk factors. Saudi J Kidney Dis Transpl. 2010;21(2):357-8.
96. Alavian SM, Hosseini-Moghaddam SM, Rahnavardi M. Hepatitis C among hemodialysis patients: A review on epidemiologic, diagnostic, and therapeutic features. Hepatitis Monthly 2007;7(3):153-62.
97. Alavian SM, Tabatabaei SV. Effects of oral levamisole as an adjuvant to hepatitis B vaccine in adults with end-stage renal disease: A meta-analysis of controlled clinical trials. Clin Ther. 2010;32(1):1-10.
98. Sali SH, Alavian SM, Hajarizadeh B. Effect of levamisole supplementation on hepatitis B virus vaccination response in hemodialysis patients. Nephrology (Carlton) 2008;13:376-9.
99. Kabir A, Alavian SM, Kashani AH. Predicting response to HBV vaccination in people with positive anti-HBc but negative HBsAg and anti-HBs. Hum Vaccin. 2008;4(5):134-38.
100. Marineau M, Tice AD, Taylor-Garcia D, Akinaka KT, Lusk H, Ona F. Culturally sensitive strategies designed to target the silent epidemic of hepatitis B in a Filipino community. Hawaii Med J. 2007;66(6):154-6.
101. Marineau M, Tice AD, Taylor-Garcia D, Akinaka KT, Lusk H, Ona F. Culturally sensitive strategiesdesigned to target the silent epidemic of hepatitis B in a Filipino community. Hawaii Med J. 2007;66(6):154-6.
102. Nishtar S. The gateway paper-proposed health reforms in Pakistan, interface considerations. J Pak Med Assoc. 2006;56:S78-93.
103. Rainey J. An evaluation of a state hepatitis prevention and control program: focus group interviews with clients. Health Promot Pract. 2007;8(3):266-72.
104. Mahboobi N, Agha-Hosseini F, Safari S, Lavanchy D, Alavian SM. Hepatitis B virus infection in dentistry: a forgotten topic. J Viral Hepat. 2010;17:307-16.